Atrium Therapeutics to present nonclinical data on PRKAG2 syndrome candidate
Atrium Therapeutics will report new data on November 6 demonstrating that its investigational therapy ATR 1072 reversed cardiac symptoms in preclinical models of PRKAG2 syndrome.
Atrium Therapeutics is set to present nonclinical findings regarding ATR 1072 at the American Heart Association Scientific Sessions in Chicago on November 6. The study demonstrates that the therapy successfully reduced cardiac glycogen accumulation and mitigated hypertrophy in a mouse model engineered to exhibit PRKAG2 syndrome.
PRKAG2 syndrome is a rare genetic condition that results in abnormal glycogen storage in the heart, leading to thickened heart muscle and cardiac arrhythmias. There are currently no approved therapies that target the genetic driver of the disease, leaving patients limited to symptomatic management.
"These findings continue to strengthen the scientific rationale for ATR 1072," said Husam Younis, Chief Scientific Officer at Atrium Therapeutics. The company is currently conducting a Phase 1/2 clinical trial, known as Corventis, to evaluate the safety and efficacy of the treatment. Initial proof-of-concept data from this trial is anticipated by the second half of 2027.